Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis

Abstract Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refra...

Full description

Bibliographic Details
Main Authors: Mauricio Sarmiento Maldonado, Pablo Ramírez Villanueva, Pablo Bertín Cortes-Monroy, Veronica Jara Arias, Katherine Soto Donoso, Pablo Uribe Gonzalez, Mauricio Ocqueteau Tachini, Jose Antonio Perez-Simón
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Experimental Hematology & Oncology
Subjects:
Ruxolitinib
Graft versus host disease
Corticoid refractoriness
Extracorporeal photopheresis
Online Access:http://link.springer.com/article/10.1186/s40164-017-0092-3

Internet

http://link.springer.com/article/10.1186/s40164-017-0092-3

Similar Items